abstract：:Programmed cell death-1 immune checkpoint inhibitor (ICI) antibody has proven to be effective in advanced non-small cell lung cancer (NSCLC) patients positive for programmed cell death-1 ligand-1. However, there are currently no reports which evaluate drug efficacy by continuous bronchoscopic observation. A 75-year-ol...

journal_title：Thoracic cancer

authors： Morikawa K,Kida H,Handa H,Inoue T,Miyazawa T,Mineshita M

更新日期：2020-05-01 00:00:00

abstract：BACKGROUND:This study aimed to compare survival between standard lobectomy and surgeons' preference sublobar resection among patients with stage I non-small cell lung cancer (NSCLC). METHODS:Medical records of patients undergoing pulmonary resection between 2006 and 2016 were reviewed retrospectively. Differences in d...

journal_title：Thoracic cancer

authors： Huang CS,Hsu PK,Chen CK,Yeh YC,Hsu HS,Shih CC,Huang BS

更新日期：2020-04-01 00:00:00

abstract：BACKGROUND:Interstitial lung disease (ILD) induced by immune checkpoint inhibitors (ICIs) is a potentially life-threatening adverse event. The purpose of this study was to evaluate whether the development of immune-related adverse events (irAEs), especially ILD, was associated with treatment efficacy and to research th...

journal_title：Thoracic cancer

authors： Sugano T,Seike M,Saito Y,Kashiwada T,Terasaki Y,Takano N,Hisakane K,Takahashi S,Tanaka T,Takeuchi S,Miyanaga A,Minegishi Y,Noro R,Kubota K,Gemma A

更新日期：2020-04-01 00:00:00

abstract：:Enhanced recovery after surgery (ERAS) is a multiprofessional, multidisciplinary and evidence-based program that aims to reduce complications, improve overall prognosis, shorten hospital stays, and promote fast recovery following major surgery. Nurses play a crucial role in the successful implementation of the ERAS pr...

journal_title：Thoracic cancer

authors： Li Y,Yan C,Li J,Wang Q,Zhang J,Qiang W,Qi D

更新日期：2020-04-01 00:00:00

abstract：BACKGROUND:CD73 induces the dephosphorylation of adenosine monophosphate converting it to adenosine, enabling malignancies to escape from immune surveillance. Although CD73 overexpression has been reported to be a poor prognostic factor in several malignancies including non-small cell lung cancer (NSCLC), its predictiv...

journal_title：Thoracic cancer

authors： Ishii H,Azuma K,Kawahara A,Kinoshita T,Matsuo N,Naito Y,Tokito T,Yamada K,Akiba J,Hoshino T

更新日期：2020-04-01 00:00:00

abstract：BACKGROUND:Several studies have previously demonstrated the survival benefit of both EGFR-TKI treatment and chemotherapy in patients with non-small cell lung cancer (NSCLC) harboring EGFR mutations. The aim of the present study was to clarify the factors influencing the treatment sequence after failure of EGFR-TKI ther...

journal_title：Thoracic cancer

authors： Mizuno T,Horinouchi H,Watanabe S,Sato J,Morita R,Murakami S,Goto Y,Kanda S,Fujiwara Y,Yamamoto N,Ohe Y

更新日期：2020-04-01 00:00:00

abstract：BACKGROUND:Tumor recurrence or residual tumor after targeted therapy is common in patients with advanced non-small cell lung cancer (NSCLC). There is a lack of high-level evidence on which type of treatment should be employed for these patients and the role of salvage surgery has not been well reported in the literatur...

journal_title：Thoracic cancer

authors： Song W,Di S,Liu J,Fan B,Zhao J,Zhou S,Chen S,Dong H,Yue C,Gong T

更新日期：2020-04-01 00:00:00

abstract：:Immune checkpoint inhibitors that block the programmed death 1/programmed death ligand 1 pathways are widely used to treat advanced lung cancers. There are seldom cases of histologic transformation reported after treatment with immunotherapy. Here, we report the case of a 69-year-old man with stage IV lung squamous ce...

journal_title：Thoracic cancer

authors： Si X,You Y,Zhang X,Wang H,Wang M,Zhang L

更新日期：2020-03-01 00:00:00

abstract：BACKGROUND:Breast cancer (BC) is a common cancer in women worldwide. Emerging evidence has indicated that circular RNA hsa-circ_0007255 (circ_0007255) is a prognostic mediator in BC progression. However, the functional role of circ_0007255 needs to be determined. METHODS:The expression of circ_0007255, microRNA (miR)-...

journal_title：Thoracic cancer

authors： Jia Q,Ye L,Xu S,Xiao H,Xu S,Shi Z,Li J,Chen Z

更新日期：2020-03-01 00:00:00

abstract：BACKGROUND:Our recent studies have indicated that miR-153-3p is downregulated in the esophageal squamous cell carcinoma (ESCC) cell lines and tissues. Upregulation of miR-153-3p was found to inhibit migration and invasion of ESCC cells. However, whether miR-153-3p regulates the cisplatin sensitivity in ESCC cells remai...

journal_title：Thoracic cancer

authors： Zuo J,Zhao M,Fan Z,Liu B,Wang Y,Li Y,Lv P,Xing L,Zhang X,Shen H

更新日期：2020-03-01 00:00:00

abstract：:Immune checkpoint inhibitors (ICIs) have been widely used in the management of malignant tumors. Programmed death 1 (PD-1)/PD-1 ligand (PD-L1) inhibitors have been introduced to treat non-small cell lung cancer (NSCLC) in recent years. Currently, PD-1/PD-L1 inhibitors are considered to have minor side effects and do n...

journal_title：Thoracic cancer

authors： Lu M,Zhang L,Li Y,Wang H,Guo X,Zhou J,Duan L,Si X,Xu Y,Zhang L

更新日期：2020-03-01 00:00:00

abstract：:This report describes the case of a 17-year-old man who developed mediastinal growing teratoma syndrome following two cycles of chemotherapy, after an initial diagnosis of primary mediastinal nonseminomatous germ cell tumor. The large, rapidly-growing mediastinal tumor was completely resected in conjunction with right...

journal_title：Thoracic cancer

authors： Kao CN,Chou SH,Huang CL,Lin CH,Chiang HH,Lee JY,Li HP,Chang PC,Liu YW

更新日期：2020-03-01 00:00:00

abstract：BACKGROUND:Nm23-H1 gene has been found to be an inhibitor of tumor metastasis in lung cancer. MicroRNAs (miRNAs) play key roles in tumor metastasis through multiple signaling pathways. This study explored whether the nm23-H1 gene could inhibit invasion and metastasis of lung cancer cells by regulating miRNA-660-5p targ...

journal_title：Thoracic cancer

authors： Ai C,Ma G,Deng Y,Zheng Q,Gen Y,Li W,Li Y,Zu L,Zhou Q

更新日期：2020-03-01 00:00:00

abstract：BACKGROUND:Epidermal growth factor receptor (EGFR) activating mutations are usually associated with DNA damage repair (DDR) deficiency. However, the precise mechanism has remained elusive. In this study, we aimed to investigate whether EGFR exon 19 deletion mutation downstream signals contributed to DDR deficiency by d...

journal_title：Thoracic cancer

authors： Zhang L,Pradhan B,Guo L,Meng F,Zhong D

更新日期：2020-02-01 00:00:00

abstract：BACKGROUND:Surgery is the standard of care for early stage non-small cell lung cancer (NSCLC). Stereotactic body radiotherapy (SBRT) is another definitive treatment option for those patients who have not been treated surgically. Comparison of approaches is being explored in NSCLC, but has yet to be compared exclusively...

journal_title：Thoracic cancer

authors： Lo H,Abel S,Finley G,Weksler B,Colonias A,Wegner RE

更新日期：2020-02-01 00:00:00

abstract：BACKGROUND:The impact of adjuvant treatment for esophageal carcinoma with tumor-negative lymph nodes after upfront radical esophagectomy is still uncertain. This study investigated the effects of postoperative radiotherapy in pT1-3N0 esophageal carcinoma after radical resection. METHOD:We retrospectively identified pT...

journal_title：Thoracic cancer

authors： Gao HJ,Shang XB,Gong L,Zhang HD,Ren P,Shi GD,Wei YC,Yu ZT

更新日期：2020-02-01 00:00:00

abstract：:Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. The unique spectrum of immune-related adverse events (IrAEs) may occur during treatment. Dermatologic toxicities appear to be one of the most prevalent immunotherapy-related adverse events. The most common symptoms are maculopapular rash and pru...

journal_title：Thoracic cancer

authors： Si X,He C,Zhang L,Liu X,Li Y,Wang H,Guo X,Zhou J,Duan L,Wang M,Zhang L

更新日期：2020-02-01 00:00:00

abstract：BACKGROUND:Non-small-cell lung cancer (NSCLC) is the most lethal type of cancer. Long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) have been identified as crucial regulators in the development of NSCLC. The aim of our study was to explore the molecular mechanism of SNHG1 to enable better treatment for NSCLC patient...

journal_title：Thoracic cancer

authors： Li X,Zheng H

更新日期：2020-02-01 00:00:00

abstract：BACKGROUND:Achaete-scute homolog 1 (ASCL1) is a basic helix-loop-helix transcription factor and is essential in the differentiation of neuroendocrine cells and neural tissues. ASCL1 is frequently overexpressed in small cell lung cancer (SCLC) and plays a crucial role in the pathogenesis of SCLC. METHODS:This study was...

journal_title：Thoracic cancer

authors： Kim JH,Lee SY,Choi JE,Do SK,Lee JH,Hong MJ,Kang HG,Lee WK,Shin KM,Jeong JY,Choi SH,Lee YH,Seo H,Yoo SS,Lee J,Cha SI,Kim CH,Park JY

更新日期：2020-01-01 00:00:00

abstract：:Meningeal carcinomatosis (MC) refers to the diffuse or multifocal spread or infiltration of malignant tumors in the pia mater. It is a special distribution type of metastatic tumors in the central nervous system and one of the important reasons of death caused by metastatic malignant tumors. Here, we report a rare cas...

journal_title：Thoracic cancer

authors： Liu H,Liu L,Zhang X,Jin S

更新日期：2020-01-01 00:00:00

abstract：BACKGROUND:To compare the efficiency and toxicity of bevacizumab by intrapleural or intravenous infusion in the management of malignant pleural effusion in patients with non-small-cell lung cancer (NSCLC). METHODS:Sensitizing mutation negative NSCLC patients with malignant pleural effusion were randomized into two gro...

journal_title：Thoracic cancer

authors： Nie K,Zhang Z,You Y,Zhuang X,Zhang C,Ji Y

更新日期：2020-01-01 00:00:00

abstract：BACKGROUND:Osimertinib (AZD9291) is a third-generation EGFR-tyrosine kinase inhibitor (TKI) that selectively inhibits the activating EGFR mutation and T790M mutation, and is currently used globally to treat EGFR-mutant non-small cell lung cancer (NSCLC). However, acquired resistance to osimertinib is inevitable. METHO...

journal_title：Thoracic cancer

authors： Hayakawa D,Takahashi F,Mitsuishi Y,Tajima K,Hidayat M,Winardi W,Ihara H,Kanamori K,Matsumoto N,Asao T,Ko R,Shukuya T,Takamochi K,Hayashi T,Suehara Y,Takeda Nakamura I,Ueno T,Kohsaka S,Mano H,Takahashi K

更新日期：2020-01-01 00:00:00

abstract：BACKGROUND:This study evaluated the efficacy and safety of retreatment with anti-programmed death 1 (anti-PD-1) antibodies in patients with advanced non-small cell lung cancer (NSCLC) after prior treatment with anti-programmed death-ligand 1 (anti-PD-L1) antibodies. METHODS:Data (N = 15) on patients' characteristics, ...

journal_title：Thoracic cancer

authors： Fujita K,Yamamoto Y,Kanai O,Okamura M,Hashimoto M,Nakatani K,Sawai S,Mio T

更新日期：2020-01-01 00:00:00

abstract：BACKGROUND:Metastatic or recurrent thyroid cancer often behaves aggressively, and approximately two-thirds of patients present with radioiodine resistance. Effective therapies to suppress thyroid cancer metastasis are urgently needed. Nevirapine has been proved to suppress tumor growth and induce differentiation in sev...

journal_title：Thoracic cancer

authors： Shang H,Zhao J,Yao J,Wang H,Wang S,Dong J,Liao L

更新日期：2019-12-01 00:00:00

abstract：:SMARCA4-deficient thoracic sarcoma (SMARCA4-DTS) is a new clinical entity characterized by SMARCA4 inactivation and has a dismal prognosis because of rapid growth. Effective treatments for SMARCA4-DTS have not yet been developed. Most recently, anti-programmed cell death 1 receptor (PD-1) blockade has been effective f...

journal_title：Thoracic cancer

authors： Takada K,Sugita S,Murase K,Kikuchi T,Oomori G,Ito R,Hayasaka N,Miyanishi K,Iyama S,Ikeda H,Kobune M,Emori M,Kato J,Hasegawa T

更新日期：2019-12-01 00:00:00

abstract：BACKGROUND:Both hypoxia and oncogenic mutations rewire tumor metabolism. In this study, glucose and glutamine metabolism-related markers were examined in stage I - resectable stage IIIA non-small cell lung cancer (NSCLC). Furthermore, expression of metabolism-related markers was correlated with mutational status to exa...

journal_title：Thoracic cancer

authors： Meijer TWH,Looijen-Salamon MG,Lok J,van den Heuvel M,Tops B,Kaanders JHAM,Span PN,Bussink J

更新日期：2019-12-01 00:00:00

abstract：BACKGROUND:Despite recent advances in treating non-small cell lung cancer (NSCLC) with immune checkpoint inhibitors (ICIs), their role in ALK-positive NSCLC patients is unclear. We investigated the efficacy of ICIs in patients with ALK-positive NSCLC. METHODS:Between 2011 and 2018, a total of 14 ALK-positive NSCLC pat...

journal_title：Thoracic cancer

authors： Heo JY,Park C,Keam B,Ock CY,Kim M,Kim TM,Kim DW,Kim SH,Kim YJ,Lee JS,Heo DS

更新日期：2019-11-01 00:00:00

abstract：BACKGROUND:Previous studies have reported that soluble fms-like tyrosine kinase-1 (sFlt-1) possesses anti-tumor effects by inhibiting angiogenesis in many cancers. Exosomes can be engineered as delivery vehicles for transferring functional biomolecules, such as proteins, lipids, and nucleic acids (DNA, mRNA, and miRNA)...

journal_title：Thoracic cancer

authors： Hao D,Li Y,Zhao G,Zhang M

更新日期：2019-10-01 00:00:00

abstract：:Immunoglobulin light-chain (AL) amyloidosis is a monoclonal plasma cell neoplasm that has a tendency to bleed easily. However, the potential risks of transbronchial biopsy in such cases have not been fully proven. Here, we report a case of parotid and intrathoracic AL amyloid tumors that presented as endobronchial pro...

journal_title：Thoracic cancer

authors： Tomono H,Soda H,Fukuda Y,Tanaka Y,Ono S,Shimada M,Iwasaki K,Hisanaga M,Yamaguchi H,Mukae H

更新日期：2019-10-01 00:00:00

abstract：BACKGROUND:Tumor mutation burden (TMB) is an important determinant and biomarker for response of targeted therapy and prognosis in patients with lung cancer. The present study aimed to determine whether radiomics signature could non-invasively predict the TMB status and driver mutations in patients with resectable earl...

journal_title：Thoracic cancer

authors： Wang X,Kong C,Xu W,Yang S,Shi D,Zhang J,Du M,Wang S,Bai Y,Zhang T,Chen Z,Ma Z,Wang J,Dong G,Sun M,Yin R,Chen F

更新日期：2019-10-01 00:00:00

abstract：BACKGROUND:The aim of this study was to investigate the feasibility of using a combination of apatinib in the treatment of non-small cell lung cancer. Apatinib is a tyrosine kinase inhibitor which selectivelyacts on vascular endothelial growth factor receptor 2 (VEGFR-2) and has shown good efficacy in a variety of mali...

journal_title：Thoracic cancer

authors： Liu M,Wang X,Li H,Xu L,Jing L,Jiang P,Liu B,Li Y

更新日期：2019-10-01 00:00:00

abstract：BACKGROUND:The efficacy of amrubicin for relapsed small-cell lung cancer (SCLC) has been reported in previous studies. Few reports, however, describe the efficacy and survival benefit of third-line amrubicin chemotherapy in patients with extensive disease (ED)-SCLC. METHODS:We retrospectively analyzed the clinical rec...

journal_title：Thoracic cancer

authors： Sonehara K,Tateishi K,Fukushima T,Komatsu M,Yamamoto H,Koizumi T,Hanaoka M

更新日期：2019-09-01 00:00:00

abstract：BACKGROUND:Most non-small cell lung cancer (NSCLC) patients relapse on anaplastic lymphoma kinase-tyrosine kinase inhibitor (ALK-TKI) therapy because of acquired resistance. Rebiopsy is recommended to provide optimal therapy after relapse for some ALK-TKI therapies; however, little clinical data exists on the clinical ...

journal_title：Thoracic cancer

authors： Haratake N,Seto T,Takamori S,Toyozawa R,Nosaki K,Miura N,Ohba T,Toyokawa G,Taguchi K,Yamaguchi M,Shimokawa M,Takenoyama M

更新日期：2019-09-01 00:00:00

abstract：:Lung cancer is globally one of the leading causes of malignant tumor-related mortality and ranks as having the highest incidence found in men and second in women. Osimertinib is a drug used to target lung cancer but its toxicity is not fully understood. Here we present a case of lung adenocarcinoma in a 78-year-old ma...

journal_title：Thoracic cancer

authors： Fan M,Mo T,Shen L,Yang L

更新日期：2019-07-01 00:00:00

abstract：BACKGROUND:The number of patients diagnosed with early stage disease (T1a or T1b) has been increasing. This study was conducted to investigate the effect of esophagectomy (ES), endoscopic therapy (ET), and radiotherapy (RT) on long-term survival in elderly patients with cT1N0M0 esophageal cancer. METHODS:We searched t...

journal_title：Thoracic cancer

authors： Qin J,Peng Y,Chen W,Ma H,Zheng Y,Li Y,Wang J

更新日期：2019-07-01 00:00:00

abstract：BACKGROUND:Growing evidence indicates that high phosphoserine phosphatase (PSPH) expression is associated with tumor prognosis in many types of cancers. However, the role of PSPH in non-small cell lung cancer (NSCLC) is unclear. The purpose of this study was to investigate the clinical significance of PSPH in NSCLC. M...

journal_title：Thoracic cancer

authors： Liao L,Yu H,Ge M,Zhan Q,Huang R,Ji X,Liang X,Zhou X

更新日期：2019-05-01 00:00:00

abstract：BACKGROUND:This study was conducted to investigate the gene expression profiles associated with thymoma to better understand the molecular mechanism underlying the pathogenesis of thymoma. METHODS:Eight patients with thymomas (type A, AB, B1, and B2) and four controls with thymic cysts were analyzed using microarray p...

journal_title：Thoracic cancer

authors： Meng FJ,Wang S,Zhang J,Yan YJ,Wang CY,Yang CR,Guan ZY,Wang CL

更新日期：2019-05-01 00:00:00

abstract：:This report describes the surgical management of a male patient with early-stage lung cancer who underwent thoracoscopic completion right lower lobectomy after previously undergoing sublobar resection for multifocal ground glass nodules of the lung. Perioperative considerations associated with the management of dense ...

journal_title：Thoracic cancer

authors： Liu YW,Chou SH,Hung JY,Kao CN,Chang PC

更新日期：2019-05-01 00:00:00

abstract：BACKGROUND:Malignant pleural mesothelioma (MPM) is a rare but aggressive tumor that originates from the pleura and has a poor prognosis. Eligible patients can benefit from surgery, but their survival is affected by many factors. Therefore, we created a graphic model that could predict the prognosis of surgically treate...

journal_title：Thoracic cancer

authors： Zhuo M,Zheng Q,Chi Y,Jia B,Zhao J,Wu M,An T,Wang Y,Li J,Zhao X,Yang X,Zhong J,Chen H,Dong Z,Wang J,Zhai X,Wang Z

更新日期：2019-05-01 00:00:00

abstract：BACKGROUND:The study was conducted to compare the clinicopathological characteristics, survival outcomes, and metastatic patterns between pulmonary large cell neuroendocrine carcinoma (LCNEC) and other non-small cell lung cancer (ONSCLC), and to identify the prognostic factors of LCNEC. METHODS:Data of patients diagno...

journal_title：Thoracic cancer

authors： Yang Q,Xu Z,Chen X,Zheng L,Yu Y,Zhao X,Chen M,Luo B,Wang J,Sun J

更新日期：2019-04-01 00:00:00